Connect with us

Health

HIV drug deal on ice over pharma firm’s price secrecy, says Doctors Without Borders

MSF halts HIV prevention deal due to drugmaker’s confidentiality demands.

ViiV Healthcare’s secrecy on pricing and terms delays access to vital treatment for vulnerable populations, causing concern.

Published

on

GENEVA, SWITZERLAND — Doctors Without Borders (MSF) said Thursday a deal aimed to bring long-term preventative HIV treatment to vulnerable populations was on hold after the drugmaker imposed pricing confidentiality.

In a statement, MSF called on ViiV Healthcare, to withdraw unacceptable conditions suddenly added to a long-negotiated purchase agreement for the preventative HIV drug cabotegravir long-acting (CAB-LA).

These conditions, including a confidentiality clause on the drug’s price and supply terms, “are not acceptable in MSF purchase agreements”, the statement said.

MSF warned that the new conditions were holding up its procurement of the drug, which it said was the most effective form of HIV prevention available today.

ViiV Healthcare is a subsidiary of British pharmaceutical giant GSK.

A spokesperson for Viiv said: “We share MSF’s ambition to enable access to Cabotegravir LA for PrEP.

“We remain committed to supporting our partners, and we’re currently working closely on contract negotiations with MSF to enable access to Cabotegravir LA for PrEP as quickly as possible.”

MSF said it had been negotiating the deal since early 2022, with the aim to first bring the highly effective drug, given as an injection every eight weeks instead of as daily pills, to vulnerable populations in Mozambique.

But a few months ago ViiV had suddenly added the confidentiality clause, it said.

It had also announced it retained the power to terminate the contract or refuse the purchase order without just reasons, which MSF said undermined supply security.

MSF is “stuck in an infuriating situation,” Helen Bygrave with the MSF Access Campaign said in the statement.

“There’s a lifesaving HIV prevention drug at our fingertips, but ViiV, the only corporation producing CAB-LA for at least the next three to four years, is deliberately putting up red tape to delay access for people in our care.”

‘Stop stalling’

In May last year, the Health Gap civil society group alleged that ViiV had set an access price for CAB-LA at US$23,000 per person per year in the United States, and at US$240-270 per person per year in low-income countries, “putting the drug far out of reach for those who need it most”.

MSF said Thursday that “the new access price is not expected to be significantly different”.

“Regardless, ViiV continues to undermine the established good practices of transparency on HIV drug prices and supply terms in its ongoing negotiations with procurers, by attempting to reinstate confidentiality clauses around the price and supply terms of CAB-LA,” it said.

The medical charity said that since it first began responding to the HIV crisis more than two decades ago, it had consistently refrained from signing such clauses, akin to Non-Disclosure Agreements (NDAs), as part of its efforts to help promote access to affordable, quality-assured treatments.

Bygrave called on ViiV to “stop stalling… so that we can make sure people in our care are offered the most effective HIV prevention as quickly as possible.”

“MSF remains open to finding an immediate solution and awaits the response from ViiV.”

— AFP

Continue Reading
Click to comment
Subscribe
Notify of
0 Comments
Newest
Oldest Most Voted
Inline Feedbacks
View all comments

Health

Malaysia reports new mpox case in man without recent international travel

Malaysia has confirmed its first mpox case of 2024 in a male patient, the Health Ministry reported. The patient is in isolation and stable, with authorities monitoring his contacts. This brings the total confirmed cases since July 2023 to ten, all from clade II.

Published

on

MALAYSIA: The Malaysian Health Ministry confirmed a new case of monkeypox (mpox) in a male citizen, marking the country’s first confirmed case of 2024.

The patient, who began showing symptoms on 11 September, is currently in isolation and in stable condition.

The ministry, in a statement issued Tuesday (17 September), revealed that the patient first experienced fever, sore throat, and cough, followed by the appearance of rashes on 12 September.

He has no recent history of international travel within the past 21 days, and authorities are in the process of identifying and monitoring his close contacts, following strict standard operating procedures (SOPs).

“Out of the 58 suspected mpox cases referred to the ministry this year, one case has been confirmed positive for mpox clade II as of 16 September,” the ministry stated.

“All 10 cases reported in Malaysia since July 2023 have been from clade II.”

The Health Ministry had earlier reported that Malaysia recorded a total of nine mpox cases since the first detection on 26 July 2023, with the most recent case reported in November 2023.

All previous cases had links to high-risk activities, but no deaths were reported.

Global Context and National Preparedness

Mpox was declared a Public Health Emergency of International Concern (PHEIC) for the second time on 14 August this year, due to the rapid spread of the clade Ib variant, particularly from the Democratic Republic of Congo (DRC) and neighboring African nations.

In response, Malaysia’s Health Ministry activated its national crisis response centre on 16 August to enhance readiness and coordinate preventive measures.

The ministry advised the public to take precautions, including maintaining personal hygiene and avoiding direct contact with individuals suspected or confirmed to be infected with mpox.

High-risk individuals experiencing symptoms such as fever, swollen lymph nodes, and rashes are urged to seek immediate medical attention.

Mpox is caused by the monkeypox virus (MPVX) and spreads through close contact with symptomatic individuals.

The incubation period is typically between 5 and 21 days, and patients remain contagious until all lesions have dried up and fallen off.

Continue Reading

Health

Singapore to offer Mpox vaccine to high-risk healthcare workers and close contacts

Singapore will offer free mpox vaccines to high-risk healthcare workers and close contacts of confirmed cases, amid concerns over the deadlier clade 1 strain. The Ministry of Health stated mask-wearing is unnecessary for the public, as the virus primarily spreads through close contact.

Published

on

Singapore has announced new measures to combat the spread of the deadlier mpox clade 1 strain, as concerns mount over its potential impact.

At a press conference on Wednesday, Health Minister Ong Ye Kung revealed that the mpox vaccine JYNNEOS will be offered to two key groups: healthcare workers at high risk of exposure and close contacts of confirmed cases.

The announcement comes as the World Health Organization (WHO) declared mpox a global public health emergency for the second time in two years due to the resurgence of clade 1 cases in Africa.

Minister Ong emphasized that while there is limited data on the virus, the government has sufficient information to implement precautionary measures. “We do not have full information on the characteristics of this virus, but we have good information on how it behaves,” he said. Ong added that Singapore’s response plan would remain flexible and adapt as the global understanding of the virus evolves.

Response Measures and Border Controls

As part of a whole-of-government approach, the Ministry of Health (MOH) has coordinated a comprehensive public health strategy to prevent the spread of mpox clade 1 in Singapore.

While no direct flights connect Singapore to countries experiencing mpox outbreaks, temperature and visual screening measures have been put in place at Changi and Seletar airports for travellers and crew arriving from affected regions. Screening at sea checkpoints has also been implemented for ships from mpox-affected areas.

Travellers are required to report any mpox-related symptoms (such as fever or rash) and provide travel history via the SG Arrival Card. Those displaying symptoms will be assessed by medical professionals at the borders and referred to hospitals if necessary.

Vaccination Strategy and Quarantine

The JYNNEOS vaccine, previously approved in Singapore for both smallpox and mpox, will be offered to two key groups. Healthcare workers at the National Centre for Infectious Diseases (NCID) and other high-risk facilities will be provided with pre-exposure prophylaxis, in addition to existing infection control protocols. Close contacts of confirmed mpox cases will receive a single vaccine dose within 14 days of exposure during their 21-day quarantine period. The MOH has assured that the current vaccine supply is sufficient to meet the needs of these priority groups.

MOH highlighted that a “significant” portion of the population—those born before 1981—may already have some immunity due to mandatory smallpox vaccinations administered in Singapore until that year.

Detection, Isolation, and Treatment

MOH has instructed all healthcare providers to be vigilant and promptly report any suspected mpox cases, especially those involving clade 1.

Suspected cases will be referred to designated hospitals for further assessment and testing, with paediatric cases directed to KK Women’s and Children’s Hospital and adult-child family groups to National University Hospital. Confirmed clade 1 cases will be isolated in healthcare facilities until they are no longer infectious to prevent further community spread.

Testing for mpox involves polymerase chain reaction (PCR) testing conducted at the National Public Health Laboratory. While there are no rapid point-of-care test kits available, cases are managed through supportive care. For severe cases, antivirals such as Tecovirimat may be used, aligning with treatment protocols in other countries.

Community Measures and Mask-Wearing

Based on current data, the virus spreads mainly through close physical contact, such as within households. Therefore, mask-wearing for the general public is not recommended unless there is significant evidence of respiratory transmission. MOH has stated that if respiratory spread becomes a concern, measures such as mask-wearing on public transport or in crowded indoor spaces may be considered.

In settings such as preschools and schools, existing infectious disease protocols—such as visual screenings for symptoms and hygiene measures—will continue to be implemented to control any potential spread. Additionally, MOH, in collaboration with the Ministry of Manpower and the National Environment Agency, has begun wastewater testing at migrant worker dormitories and the Onboard Centre to detect any presence of mpox.

Ongoing Surveillance and Preparedness

MOH will continue to work closely with international counterparts to monitor the evolving mpox situation. Border measures, detection protocols, and vaccination strategies will be adjusted as needed to safeguard Singapore’s public health.

As of now, Singapore has not detected any clade 1 cases, with all 14 mpox cases this year involving the less severe clade 2 subtype. However, Minister Ong stressed the importance of vigilance, particularly in protecting vulnerable groups such as children and the immunocompromised, should clade 1 reach Singapore.

“Our best course of action is to suppress the spread, provide proper treatment, and have an effective vaccination strategy in place,” Ong said. Despite the concern surrounding mpox, Ong reassured the public that it is unlikely to cause the level of disruption seen during COVID-19.

Continue Reading

Trending